CorMedix Inks Commercial Supply Agreement with Top-Tier Dialysis Provider
Shares in biopharmaceutical company, CorMedix (Nasdaq: CRMD), rose in morning trading on Tuesday after the company announced that it has entered into a multi-year commercial supply contract with a top-tier dialysis provider for the supply of DefenCath® (taurolidine and heparin). DefenCath® is the first FDA-approved catheter lock solution (CLS) designed to reduce the incidence of catheter-related bloodstream infections in adults receiving chronic hemodialysis.
CorMedix received NDA approval of DefenCath® in November 2023, and began commercializing the product in the inpatient setting in April 2024. CorMedix expects to begin commercialization in outpatient dialysis clinics in July.
Commenting on the news, CorMedix CEO, Joseph Todisco, said, “I am pleased with the progress we are making in our discussions with outpatient dialysis providers, and solidifying this agreement ensures that potentially thousands of patients at risk for a catheter related bloodstream infection will have access to DefenCath. Utimately our goal is to ensure the broadest access possible to this important infection reduction mechanism.”
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and anticipates launch in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
